Dayang Chem (Hangzhou) Co., Ltd.
China
Product Name: Benzamide,N-[2-[4-(5-chloro-2,3-dihydro- 2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]- ethyl]-4-fluoro-
Price: $Inquiry/100g $Inquiry/1kg $Inquiry/100kg $Inquiry/1000kg
Purity: 98.0%
Stocking Period: Inquiry
Contact: Ms Wang

59831-65-1

59831-65-1 structure

Name: halopemide
Chemical Name: N-[2-[4-(5-chloro-2-oxo-3H-benzimidazol-1-yl)piperidin-1-yl]ethyl]-4-fluorobenzamide
CAS Number: 59831-65-1
Molecular Formula: C₂₁H₂₂ClFN₄O₂
Molecular Weight: 416.876
Catalog: Signaling Pathways GPCR/G Protein Dopamine Receptor
Create Date: 2018-08-07 21:51:07
Modify Date: 2024-01-05 19:52:12
Halopemide is a potent phospholipase D (PLD) inhibitor, with IC50s of 220 and 310 nM for human PLD1 and PLD2, respectively. Halopemid is a dopamine receptors antagonist, and acts a psychotropic agent[1][2].

Name	N-[2-[4-(5-chloro-2-oxo-3H-benzimidazol-1-yl)piperidin-1-yl]ethyl]-4-fluorobenzamide
Synonyms	halopemide ( N-<2-<4-(5-chloro-2-oxo-1-benzimidazolinyl)piperidino>ethyl>-p-fluorobenzamide ) Halopemidum Halopemida N-{2-[4-(5-Chloro-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)-1-piperidinyl]ethyl}-4-fluorobenzamide N-(2-(4-(5-Chloro-2-oxo-1-benzimidazolinyl)piperidino)ethyl)-p-fluorobenzamide 5-chloro-1-{1-[2-(4-fluoro-benzoylamino)-ethyl]-piperidin-4-yl}-1,3-dihydro-benzoimidazol-2-one N-2-[4-(5-chloro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]ethyl-4-fluoro benzamide N-{2-[4-(5-Chloro-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidin-1-yl]ethyl}-4-fluorobenzamide R 34,301 Benzamide, N-[2-[4-(5-chloro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]ethyl]-4-fluoro- halopemide Halopemide (USAN/INN) N-[2-[4-(5-Chloro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]ethyl]-4-fluorobenzamide

Description	Halopemide is a potent phospholipase D (PLD) inhibitor, with IC50s of 220 and 310 nM for human PLD1 and PLD2, respectively. Halopemid is a dopamine receptors antagonist, and acts a psychotropic agent[1][2].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Metabolic Enzyme/Protease >> Phospholipase Signaling Pathways >> GPCR/G Protein >> Dopamine Receptor Signaling Pathways >> Neuronal Signaling >> Dopamine Receptor Research Areas >> Neurological Disease
Target	PLD1:220 nM (IC50) PLD2:310 nM (IC50) dopamine receptors
In Vitro	Halopemide (1-2 μM; 21 day) affects calcification in transdifferentiated MOVAS cells[3].
In Vivo	Halopemide (10 mg/kg; p.o.) induces dyskinesias in the majority of monkeys tested[2].
References	[1]. Scott SA, et al. Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. Nat Chem Biol. 2009 Feb;5(2):108-17. [2]. Neale R, et al. Acute dyskinesias in monkeys elicited by halopemide, mezilamine and the "antidyskinetic" drugs, oxiperomide and tiapride. Psychopharmacology (Berl). 1981;75(3):254-7. [3]. Skafi N, et al. Phospholipase D: A new mediator during high phosphate-induced vascular calcification associated with chronic kidney disease. J Cell Physiol. 2019 Apr;234(4):4825-4839.

Symbol	GHS07
Signal Word	Warning
Hazard Statements	H302
Hazard Codes	Xn
RIDADR	NONH for all modes of transport